Vogenx, Inc. (NASDAQ:VOGX)
| Market Cap | 206.22M+14.1% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 13.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,812 |
| Open | 16.20 |
| Previous Close | 16.16 |
| Day's Range | 14.83 - 16.20 |
| 52-Week Range | 12.95 - 38.41 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About VOGX
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
$VOGX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VOGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VOGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VOGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VOGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VOGX from public contracts
Source: USAspending.gov
VOGX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VOGX’s recent data — informational, not investment advice